Phenominer Database Results (161 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
SHRSP/A3N plasma aldosterone level controlled sodium content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. blood aldosterone amount male 182 days-210 days 8 347.0 pg/ml 72.0 203.65 radioimmunoassay 0.0 0 107938 3100
SHRSP/A3N plasma aldosterone level controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) and controlled enrasentan content diet (1200 ppm) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. blood aldosterone amount male 182 days-210 days 8 146.0 pg/ml 26.0 73.54 radioimmunoassay 0.0 0 107939 3100
SHRSP/A3N plasma proANF 31-67 peptide level control condition Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. blood atrial natriuretic factor amount male 182 days-210 days 8 231.0 pg/ml 45.0 127.28 radioimmunoassay 0.0 0 107941 3100
SHRSP/A3N ratio of deaths related to chronic hypertension to total study population during a period of time control condition Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total life span male 168 days-189 days 25 0.0 % unspecified method 0.0 0 ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) 107517 3090
SHRSP/A3N urine total protein excretion rate controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) and controlled fat content diet (24.5 %) (between 35 and 49 days) and eprosartan (60 mg/kg/d) (between 35 and 49 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total urine protein amount male 119 days-154 days 0 22.0 mg/d 2.0 urine protein analysis 86400.0 0 107521 3090
SHRSP/A3N body weight controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and vehicle control condition (for 42 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. body mass male 126 days-147 days 0 254.0 g 7.0 body weighing method 0.0 0 107527 3090
SHRSP/A3N kidney weight control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass male 126 days-182 days 0 2.46 g 0.14 post excision weight measurement kidney 0.0 0 107530 3090
SHRSP/A3N both kidneys wet weight to body weight ratio controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass male 126 days-182 days 0 13.0 g/kg 0.7 post excision weight measurement kidney 0.0 0 107535 3090
SHRSP/A3N both kidneys wet weight to body weight ratio controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass male 126 days-182 days 0 8.8 g/kg 0.4 post excision weight measurement kidney 0.0 0 107536 3090
SHRSP/A3N kidney total tubule cast count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 4.0 /section 3.0 ex vivo light microscopy with histochemistry 0.0 0 107556 3090
SHRSP/A3N renal fibrosis foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 16.4 /section 1.4 ex vivo light microscopy with histochemistry 0.0 0 107559 3090
SHRSP/A3N systolic blood pressure reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. arterial blood pressure trait female 120 days-140 days 15 94.0 mmHg 10.0 38.73 tail cuff plethysmography 0.0 0 107571 3093
SHRSP/A3N body weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. body mass male 120 days-140 days 10 254.0 g 11.0 34.79 body weighing method 0.0 0 107573 3093
SHRSP/A3N pituitary gland weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. pituitary gland mass female 120 days-140 days 24 0.01 g 0.0 0.0 post excision weight measurement 0.0 0 107578 3093
SHRSP/A3N thymus weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. thymus mass male 120 days-140 days 24 0.14 g 0.02 0.11 post excision weight measurement 0.0 0 107584 3093
SHRSP/A3N kidney weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. kidney mass female 120 days-140 days 24 0.81 g 0.01 0.05 post excision weight measurement 0.0 0 107594 3093
SHRSP/A3N serum creatine kinase activity level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood creatine kinase amount male 120 days-140 days 24 120.0 U/l 11.0 53.89 automated serum analysis 0.0 0 107600 3093
SHRSP/A3N serum creatine kinase activity level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood creatine kinase amount female 120 days-140 days 15 141.0 U/l 16.0 61.97 automated serum analysis 0.0 0 107603 3093
SHRSP/A3N serum aspartate aminotransferase activity level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood aspartate transaminase amount female 120 days-140 days 15 166.0 U/l 5.0 19.36 automated serum analysis 0.0 0 107607 3093
SHRSP/A3N heart rate controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) and controlled carvedilol content diet (2400 ppm) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 189 days-210 days 0 254.0 beats/min 10.0 transthoracic echocardiography 0.0 0 high salt high fat diet +carvedilol 107129 3075
SHRSP/A3N end-diastolic volume controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 203 days-224 days 8 0.61 ml 0.02 0.06 transthoracic echocardiography 0.0 0 high salt high fat diet 107133 3075
SHRSP/A3N kidney glomerular lesion count control condition Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney glomerulus integrity trait male 210 days-224 days 0 6.0 /section 2.0 ex vivo light microscopy with histochemistry 0.0 0 107476 3088
SHRSP/A3N heart wet weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. heart mass female 120 days-140 days 15 0.83 g 0.04 0.14 post excision weight measurement 0.0 0 107591 3093
SHRSP/A3N pituitary gland weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. pituitary gland mass male 120 days-140 days 24 0.01 g 0.0 0.0 post excision weight measurement 0.0 0 107576 3093
SHRSP/A3N serum lactate dehydrogenase activity level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood lactate dehydrogenase amount male 120 days-140 days 24 110.0 U/l 12.0 58.79 automated serum analysis 0.0 0 107612 3093
SHRSP/A3N serum total cholesterol level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood cholesterol amount male 120 days-140 days 24 87.0 mg/dl 2.0 9.8 serum total cholesterol measurement test 0.0 0 107624 3093
SHRSP/A3N serum glucose level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood glucose amount male 120 days-140 days 24 146.0 mg/dl 2.0 9.8 automated serum analysis 0.0 0 107628 3093
SHRSP/A3N serum glucose level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood glucose amount female 120 days-140 days 24 145.0 mg/dl 3.0 14.7 automated serum analysis 0.0 0 107630 3093
SHRSP/A3N serum glucose level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood glucose amount female 120 days-140 days 15 194.0 mg/dl 17.0 65.84 automated serum analysis 0.0 0 107631 3093
SHRSP/A3N interstitial nephritis foci count control condition Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 4.9 /section 1.0 ex vivo light microscopy with histochemistry 0.0 0 107550 3090
SHRSP/A3N interstitial nephritis foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 6.6 /section 2.3 ex vivo light microscopy with histochemistry 0.0 0 foci of interstitial nephritis 107489 3088
SHRSP/A3N renal fibrosis foci count control condition Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 20.0 /section 2.0 ex vivo light microscopy with histochemistry 0.0 0 foci of renal fibrosis 107496 3088
SHRSP/A3N end-diastolic volume controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) and controlled carvedilol content diet (2400 ppm) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 189 days-210 days 0 0.96 ml 0.02 transthoracic echocardiography 0.0 0 high salt high fat diet +carvedilol 107121 3075
SHRSP/A3N serum total cholesterol level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood cholesterol amount male 120 days-140 days 10 139.0 mg/dl 4.0 12.65 serum total cholesterol measurement test 0.0 0 107625 3093
SHRSP/A3N serum urea nitrogen level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood urea nitrogen amount male 120 days-140 days 24 19.0 mg/dl 1.0 4.9 automated serum analysis 0.0 0 107632 3093
SHRSP/A3N kidney weight controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass male 126 days-182 days 0 2.77 g 0.2 post excision weight measurement kidney 0.0 0 107532 3090
SHRSP/A3N kidney total tubule cast count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 349.0 /section 45.0 ex vivo light microscopy with histochemistry 0.0 0 107555 3090
SHRSP/A3N renal fibrosis foci count control condition Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 7.4 /section 0.4 ex vivo light microscopy with histochemistry 0.0 0 107558 3090
SHRSP/A3N kidney weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. kidney mass male 120 days-140 days 24 1.39 g 0.03 0.13 post excision weight measurement 0.0 0 107592 3093
SHRSP/A3N kidney weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. kidney mass male 120 days-140 days 10 1.3 g 0.01 0.03 post excision weight measurement 0.0 0 107593 3093
SHRSP/A3N serum creatine kinase activity level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood creatine kinase amount female 120 days-140 days 24 111.0 U/l 9.0 44.09 automated serum analysis 0.0 0 107602 3093
SHRSP/A3N serum aspartate aminotransferase activity level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood aspartate transaminase amount male 120 days-140 days 24 46.0 U/l 8.0 39.19 automated serum analysis 0.0 0 107604 3093
SHRSP/A3N serum aspartate aminotransferase activity level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood aspartate transaminase amount female 120 days-140 days 24 51.0 U/l 6.0 29.39 automated serum analysis 0.0 0 107606 3093
SHRSP/A3N net sodium influx to blood lymphocyte dry weight ratio per unit time control condition Furspan PB, etal., J Hypertens. 1987 Jun;5(3):293-7. doi: 10.1097/00004872-198706000-00005. sodium ion homeostasis trait both 180 days-270 days 15 8.24 mmol/kg/h 3.8 14.72 flame photometry 0.0 0 107641 3094
SHRSP/A3N heart rate controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 189 days-210 days 0 277.0 beats/min 6.0 transthoracic echocardiography 0.0 0 high salt high fat diet 107130 3075
SHRSP/A3N systolic blood pressure controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and vehicle control condition (for 84 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. arterial blood pressure trait male 168 days-189 days 6 serial mean 284.0 mmHg 8.0 19.6 tail cuff plethysmography tail 0.0 0 average 3 week intervals for 12 weeks 107499 3090
SHRSP/A3N both testes wet weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. testis mass male 120 days-140 days 24 1.69 g 0.02 0.09 post excision weight measurement 0.0 0 107596 3093
SHRSP/A3N both testes wet weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. testis mass male 120 days-140 days 10 1.57 g 0.05 0.16 post excision weight measurement 0.0 0 107597 3093
SHRSP/A3N heart wet weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. heart mass male 120 days-140 days 24 1.41 g 0.02 0.11 post excision weight measurement 0.0 0 107588 3093
SHRSP/A3N serum lactate dehydrogenase activity level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood lactate dehydrogenase amount male 120 days-140 days 10 227.0 U/l 43.0 135.98 automated serum analysis 0.0 0 107613 3093
SHRSP/A3N serum free fatty acids level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood free fatty acid amount male 120 days-140 days 24 180.0 mmol/l 17.0 83.28 automated serum analysis 0.0 0 107616 3093
SHRSP/A3N serum free fatty acids level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood free fatty acid amount male 120 days-140 days 10 485.0 mmol/l 42.0 132.82 automated serum analysis 0.0 0 107617 3093
SHRSP/A3N serum triglyceride level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood triglyceride amount male 120 days-140 days 10 145.0 mg/dl 7.0 22.14 automated serum analysis 0.0 0 107621 3093
SHRSP/A3N serum glucose level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood glucose amount male 120 days-140 days 10 223.0 mg/dl 14.0 44.27 automated serum analysis 0.0 0 107629 3093
SHRSP/A3N serum urea nitrogen level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood urea nitrogen amount female 120 days-140 days 15 23.0 mg/dl 2.0 7.75 automated serum analysis 0.0 0 107635 3093
SHRSP/A3N both adrenal glands wet weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. adrenal gland mass male 120 days-140 days 24 23.0 mg 1.0 4.9 post excision weight measurement 0.0 0 107580 3093
SHRSP/A3N systolic blood pressure standard condition (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. arterial blood pressure trait male 203 days-224 days 10 253.0 mmHg 9.0 28.46 tail cuff plethysmography tail 0.0 0 standard rat chow 107097 3075
SHRSP/A3N heart rate controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) then controlled carvedilol content diet (2400 ppm) (for 42 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 203 days-224 days 8 236.0 beats/min 8.0 22.63 transthoracic echocardiography 0.0 0 hsfd +carvedilol reversal 107138 3075
SHRSP/A3N interstitial nephritis foci count control condition Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 3.1 /section 0.7 ex vivo light microscopy with histochemistry 0.0 0 foci of interstitial nephritis 107488 3088
SHRSP/A3N interstitial nephritis foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 2.4 /section 0.8 ex vivo light microscopy with histochemistry 0.0 0 foci of interstitial nephritis 107490 3088
SHRSP/A3N kidney total tubule cast count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 350.0 /section 80.0 ex vivo light microscopy with histochemistry 0.0 0 total tubular casts 107493 3088
SHRSP/A3N renal fibrosis foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 15.0 /section 2.0 ex vivo light microscopy with histochemistry 0.0 0 foci of renal fibrosis 107498 3088
SHRSP/A3N body weight controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. body mass male 203 days-224 days 10 367.0 g 10.0 31.62 body weighing method 0.0 0 high salt high fat diet +carvedilol 107103 3075
SHRSP/A3N end-systolic volume standard condition (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 189 days-210 days 0 0.23 ml 0.01 transthoracic echocardiography 0.0 0 standard rat chow 107127 3075
SHRSP/A3N plasma proANF 31-67 peptide level controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. blood atrial natriuretic factor amount male 182 days-210 days 8 441.0 pg/ml 71.0 200.82 radioimmunoassay 0.0 0 107942 3100
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) and controlled enrasentan content diet (1200 ppm) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. total life span male 182 days-210 days 20 5.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107935 3100
SHRSP/A3N plasma aldosterone level controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) and controlled enrasentan content diet (2400 ppm) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. blood aldosterone amount male 182 days-210 days 8 151.0 pg/ml 27.0 76.37 radioimmunoassay 0.0 0 107940 3100
SHRSP/A3N heart rate standard condition (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 189 days-210 days 0 278.0 beats/min 4.0 transthoracic echocardiography 0.0 0 standard rat chow 107131 3075
SHRSP/A3N end-diastolic volume controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) then controlled carvedilol content diet (2400 ppm) (for 42 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 203 days-224 days 8 1.08 ml 0.07 0.2 transthoracic echocardiography 0.0 0 hsfd +carvedilol reversal 107134 3075
SHRSP/A3N ratio of deaths related to chronic hypertension to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and eprosartan (60 mg/kg/d) (for 84 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total life span male 168 days-189 days 25 0.0 % unspecified method 0.0 0 ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) 107519 3090
SHRSP/A3N kidney total tubule cast count control condition Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 21.0 /section 5.0 ex vivo light microscopy with histochemistry 0.0 0 107554 3090
SHRSP/A3N pituitary gland weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. pituitary gland mass female 120 days-140 days 15 0.01 g 0.0 0.0 post excision weight measurement 0.0 0 107579 3093
SHRSP/A3N kidney weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. kidney mass female 120 days-140 days 15 0.72 g 0.02 0.09 post excision weight measurement 0.0 0 107595 3093
SHRSP/A3N serum alanine aminotransferase activity level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood alanine transaminase amount male 120 days-140 days 24 70.0 U/l 6.0 29.39 automated serum analysis 0.0 0 107608 3093
SHRSP/A3N serum alanine aminotransferase activity level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood alanine transaminase amount male 120 days-140 days 10 264.0 U/l 62.0 196.06 automated serum analysis 0.0 0 107609 3093
SHRSP/A3N systolic blood pressure control condition Furspan PB, etal., J Hypertens. 1987 Jun;5(3):293-7. doi: 10.1097/00004872-198706000-00005. arterial blood pressure trait both 141 days 7 194.0 mmHg 16.7 44.18 tail cuff plethysmography 0.0 0 107638 3094
SHRSP/A3N urine total protein excretion rate controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. urine protein amount male 210 days-224 days 0 251.0 mg/d 120.0 urine protein analysis 86400.0 0 metabolic cage; sulfosalicylic acid method 107473 3088
SHRSP/A3N kidney glomerular lesion count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney glomerulus integrity trait male 210 days-224 days 0 4.0 /section 2.0 ex vivo light microscopy with histochemistry 0.0 0 107478 3088
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. total life span male 182 days-210 days 20 65.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107934 3100
SHRSP/A3N plasma aldosterone level control condition Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. blood aldosterone amount male 182 days-210 days 8 178.0 pg/ml 12.0 33.94 radioimmunoassay 0.0 0 107937 3100
SHRSP/A3N systolic blood pressure controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and eprosartan (60 mg/kg/d) (for 84 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. arterial blood pressure trait male 168 days-189 days 6 serial mean 250.0 mmHg 9.0 22.05 tail cuff plethysmography tail 0.0 0 average 3 week intervals for 12 weeks 107500 3090
SHRSP/A3N both adrenal glands wet weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. adrenal gland mass male 120 days-140 days 10 24.0 mg 1.0 3.16 post excision weight measurement 0.0 0 107581 3093
SHRSP/A3N serum triglyceride level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood triglyceride amount male 120 days-140 days 24 97.0 mg/dl 5.0 24.49 automated serum analysis 0.0 0 107620 3093
SHRSP/A3N serum urea nitrogen level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood urea nitrogen amount male 120 days-140 days 10 33.0 mg/dl 6.0 18.97 automated serum analysis 0.0 0 107633 3093
SHRSP/A3N serum urea nitrogen level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood urea nitrogen amount female 120 days-140 days 24 24.0 mg/dl 1.0 4.9 automated serum analysis 0.0 0 107634 3093
SHRSP/A3N kidney glomerular lesion count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney glomerulus integrity trait male 126 days-182 days 0 1.4 /section 1.0 ex vivo light microscopy with histochemistry renal glomerulus 0.0 0 107540 3090
SHRSP/A3N interstitial nephritis foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 8.5 /section 1.2 ex vivo light microscopy with histochemistry 0.0 0 107551 3090
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. total life span male 203 days-224 days 20 0.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107112 3075
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. total life span male 203 days-224 days 20 55.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107113 3075
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time standard condition (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. total life span male 203 days-224 days 20 0.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107114 3075
SHRSP/A3N end-systolic volume controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) then controlled carvedilol content diet (2400 ppm) (for 42 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 203 days-224 days 8 0.36 ml 0.07 0.2 transthoracic echocardiography 0.0 0 hsfd +carvedilol reversal 107136 3075
SHRSP/A3N kidney tubule regeneration foci count control condition Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 5.8 /section 1.8 ex vivo light microscopy with histochemistry 0.0 0 foci of tubular regeneration 107484 3088
SHRSP/A3N kidney tubule regeneration foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 6.4 /section 1.0 ex vivo light microscopy with histochemistry 0.0 0 foci of tubular regeneration 107485 3088
SHRSP/A3N kidney total tubule cast count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 21.0 /section 11.0 ex vivo light microscopy with histochemistry 0.0 0 total tubular casts 107494 3088
SHRSP/A3N end-systolic volume controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) and controlled carvedilol content diet (2400 ppm) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 189 days-210 days 0 0.28 ml 0.03 transthoracic echocardiography 0.0 0 high salt high fat diet +carvedilol 107125 3075
SHRSP/A3N end-systolic volume controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 189 days-210 days 0 0.29 ml 0.04 transthoracic echocardiography 0.0 0 high salt high fat diet 107126 3075
SHRSP/A3N ratio of deaths related to chronic hypertension to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 63 days) and controlled fat content diet (24.5 %) (for 63 days) and vehicle control condition (for 63 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total life span male 147 days-168 days 25 95.0 % unspecified method 0.0 0 ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) 107518 3090
SHRSP/A3N urine total protein excretion rate controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) and controlled fat content diet (24.5 %) (between 35 and 49 days) and vehicle control condition (between 35 and 49 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total urine protein amount male 119 days-154 days 0 127.0 mg/d 13.0 urine protein analysis 86400.0 0 107520 3090
SHRSP/A3N body weight control condition (for 42 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. body mass male 126 days-147 days 0 293.0 g 4.0 body weighing method 0.0 0 107526 3090
SHRSP/A3N kidney glomerular lesion count control condition Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney glomerulus integrity trait male 126 days-182 days 0 8.8 /section 2.7 ex vivo light microscopy with histochemistry renal glomerulus 0.0 0 107538 3090
SHRSP/A3N renal fibrosis foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 7.1 /section 0.3 ex vivo light microscopy with histochemistry 0.0 0 107560 3090
SHRSP/A3N systolic blood pressure control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. arterial blood pressure trait male 120 days-140 days 24 244.0 mmHg 4.0 19.6 tail cuff plethysmography 0.0 0 107568 3093
SHRSP/A3N systolic blood pressure reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. arterial blood pressure trait male 120 days-140 days 10 147.0 mmHg 10.0 31.62 tail cuff plethysmography 0.0 0 107569 3093
SHRSP/A3N thymus weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. thymus mass male 120 days-140 days 10 0.07 g 0.01 0.03 post excision weight measurement 0.0 0 107585 3093
SHRSP/A3N thymus weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. thymus mass female 120 days-140 days 24 0.17 g 0.01 0.02 post excision weight measurement 0.0 0 107586 3093
SHRSP/A3N thymus weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. thymus mass female 120 days-140 days 15 0.05 g 0.02 0.06 post excision weight measurement 0.0 0 107587 3093
SHRSP/A3N serum creatine kinase activity level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood creatine kinase amount male 120 days-140 days 10 164.0 U/l 23.0 72.73 automated serum analysis 0.0 0 107601 3093
SHRSP/A3N systolic blood pressure control condition Furspan PB, etal., J Hypertens. 1987 Jun;5(3):293-7. doi: 10.1097/00004872-198706000-00005. arterial blood pressure trait both 180 days-270 days 13 207.0 mmHg 25.2 90.86 tail cuff plethysmography 0.0 0 107637 3094
SHRSP/A3N net potassium efflux to blood lymphocyte dry weight ratio per unit time controlled hydralazine content drinking water (100 mg/l) (for 60 days) and controlled hydrochlorothiazide content drinking water (100 mg/l) (for 60 days) then controlled hydralazine content drinking water (200 mg/l) (for 60 days) and controlled hydrochlorothiazide content drinking water (200 mg/l) (for 60 days) Furspan PB, etal., J Hypertens. 1987 Jun;5(3):293-7. doi: 10.1097/00004872-198706000-00005. potassium ion homeostasis trait both 141 days 6 12.2 mmol/kg/h 1.2 2.94 flame photometry 0.0 0 107645 3094
SHRSP/A3N kidney glomerular lesion count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney glomerulus integrity trait male 210 days-224 days 0 31.0 /section 5.0 ex vivo light microscopy with histochemistry 0.0 0 107477 3088
SHRSP/A3N ovary wet weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. ovary mass female 120 days-140 days 15 34.0 mg 7.0 27.11 post excision weight measurement 0.0 0 107599 3093
SHRSP/A3N net potassium efflux to blood lymphocyte dry weight ratio per unit time control condition Furspan PB, etal., J Hypertens. 1987 Jun;5(3):293-7. doi: 10.1097/00004872-198706000-00005. potassium ion homeostasis trait both 141 days 7 12.3 mmol/kg/h 1.4 3.7 flame photometry 0.0 0 107644 3094
SHRSP/A3N body weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. body mass female 120 days-140 days 15 158.0 g 14.0 54.22 body weighing method 0.0 0 107575 3093
SHRSP/A3N both adrenal glands wet weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. adrenal gland mass female 120 days-140 days 15 35.0 mg 4.0 15.49 post excision weight measurement 0.0 0 107583 3093
SHRSP/A3N heart wet weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. heart mass male 120 days-140 days 10 1.3 g 0.02 0.05 post excision weight measurement 0.0 0 107589 3093
SHRSP/A3N systolic blood pressure controlled hydralazine content drinking water (100 mg/l) (for 60 days) and controlled hydrochlorothiazide content drinking water (100 mg/l) (for 60 days) then controlled hydralazine content drinking water (200 mg/l) (for 60 days) and controlled hydrochlorothiazide content drinking water (200 mg/l) (for 60 days) Furspan PB, etal., J Hypertens. 1987 Jun;5(3):293-7. doi: 10.1097/00004872-198706000-00005. arterial blood pressure trait both 141 days 6 131.0 mmHg 5.6 13.72 tail cuff plethysmography 0.0 0 107639 3094
SHRSP/A3N serum triglyceride level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood triglyceride amount female 120 days-140 days 24 92.0 mg/dl 7.0 34.29 automated serum analysis 0.0 0 107622 3093
SHRSP/A3N serum triglyceride level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood triglyceride amount female 120 days-140 days 15 134.0 mg/dl 21.0 81.33 automated serum analysis 0.0 0 107623 3093
SHRSP/A3N serum total cholesterol level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood cholesterol amount female 120 days-140 days 15 147.0 mg/dl 4.0 15.49 serum total cholesterol measurement test 0.0 0 107627 3093
SHRSP/A3N kidney tubule regeneration foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 0.0 /section 0.0 ex vivo light microscopy with histochemistry 0.0 0 107548 3090
SHRSP/A3N interstitial nephritis foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 1.0 /section 0.4 ex vivo light microscopy with histochemistry 0.0 0 107552 3090
SHRSP/A3N end-systolic volume controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 203 days-224 days 8 0.25 ml 0.02 0.06 transthoracic echocardiography 0.0 0 high salt high fat diet 107135 3075
SHRSP/A3N heart rate controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 203 days-224 days 8 285.0 beats/min 15.0 42.43 transthoracic echocardiography 0.0 0 high salt high fat diet 107137 3075
SHRSP/A3N kidney tubule regeneration foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 1.9 /section 1.3 ex vivo light microscopy with histochemistry 0.0 0 foci of tubular regeneration 107486 3088
SHRSP/A3N kidney total tubule cast count control condition Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 72.0 /section 18.0 ex vivo light microscopy with histochemistry 0.0 0 total tubular casts 107492 3088
SHRSP/A3N systolic blood pressure controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. arterial blood pressure trait male 203 days-224 days 10 260.0 mmHg 6.0 18.97 tail cuff plethysmography tail 0.0 0 107095 3075
SHRSP/A3N body weight controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and eprosartan (60 mg/kg/d) (for 42 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. body mass male 126 days-147 days 0 298.0 g 2.0 body weighing method 0.0 0 107528 3090
SHRSP/A3N kidney weight controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass male 126 days-182 days 0 2.65 g 0.1 post excision weight measurement kidney 0.0 0 107531 3090
SHRSP/A3N both kidneys wet weight to body weight ratio control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass male 126 days-182 days 0 7.1 g/kg 0.2 post excision weight measurement kidney 0.0 0 107534 3090
SHRSP/A3N kidney glomerular lesion count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney glomerulus integrity trait male 126 days-182 days 0 76.5 /section 7.0 ex vivo light microscopy with histochemistry renal glomerulus 0.0 0 107539 3090
SHRSP/A3N systolic blood pressure control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. arterial blood pressure trait female 120 days-140 days 24 230.0 mmHg 6.0 29.39 tail cuff plethysmography 0.0 0 107570 3093
SHRSP/A3N body weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. body mass male 120 days-140 days 24 316.0 g 9.0 44.09 body weighing method 0.0 0 107572 3093
SHRSP/A3N pituitary gland weight reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. pituitary gland mass male 120 days-140 days 10 0.01 g 0.0 0.0 post excision weight measurement 0.0 0 107577 3093
SHRSP/A3N serum aspartate aminotransferase activity level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood aspartate transaminase amount male 120 days-140 days 10 123.0 U/l 24.0 75.89 automated serum analysis 0.0 0 107605 3093
SHRSP/A3N serum alanine aminotransferase activity level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood alanine transaminase amount female 120 days-140 days 24 84.0 U/l 7.0 34.29 automated serum analysis 0.0 0 107610 3093
SHRSP/A3N serum alanine aminotransferase activity level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood alanine transaminase amount female 120 days-140 days 15 285.0 U/l 19.0 73.59 automated serum analysis 0.0 0 107611 3093
SHRSP/A3N urine total protein excretion rate control condition Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. urine protein amount male 210 days-224 days 0 51.0 mg/d 10.0 urine protein analysis 86400.0 0 metabolic cage; sulfosalicylic acid method 107472 3088
SHRSP/A3N urine total protein excretion rate controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. urine protein amount male 210 days-224 days 0 37.0 mg/d 15.0 urine protein analysis 86400.0 0 metabolic cage; sulfosalicylic acid method 107474 3088
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time control condition Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. total life span male 182 days-210 days 20 0.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107933 3100
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) and controlled enrasentan content diet (2400 ppm) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. total life span male 182 days-210 days 20 10.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107936 3100
SHRSP/A3N ovary wet weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. ovary mass female 120 days-140 days 24 29.0 mg 1.0 4.9 post excision weight measurement 0.0 0 107598 3093
SHRSP/A3N heart wet weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. heart mass female 120 days-140 days 24 1.06 g 0.04 0.2 post excision weight measurement 0.0 0 107590 3093
SHRSP/A3N body weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. body mass female 120 days-140 days 24 207.0 g 4.0 19.6 body weighing method 0.0 0 107574 3093
SHRSP/A3N both adrenal glands wet weight control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. adrenal gland mass female 120 days-140 days 24 29.0 mg 1.0 4.9 post excision weight measurement 0.0 0 107582 3093
SHRSP/A3N net potassium efflux to blood lymphocyte dry weight ratio per unit time control condition Furspan PB, etal., J Hypertens. 1987 Jun;5(3):293-7. doi: 10.1097/00004872-198706000-00005. potassium ion homeostasis trait both 180 days-270 days 15 14.69 mmol/kg/h 7.7 29.82 flame photometry 0.0 0 107643 3094
SHRSP/A3N serum lactate dehydrogenase activity level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood lactate dehydrogenase amount female 120 days-140 days 24 96.0 U/l 8.0 39.19 automated serum analysis 0.0 0 107614 3093
SHRSP/A3N serum lactate dehydrogenase activity level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood lactate dehydrogenase amount female 120 days-140 days 15 212.0 U/l 12.0 46.48 automated serum analysis 0.0 0 107615 3093
SHRSP/A3N serum free fatty acids level reproduction condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood free fatty acid amount female 120 days-140 days 15 796.0 mmol/l 61.0 236.25 automated serum analysis 0.0 0 107619 3093
SHRSP/A3N serum total cholesterol level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood cholesterol amount female 120 days-140 days 24 98.0 mg/dl 1.0 4.9 serum total cholesterol measurement test 0.0 0 107626 3093
SHRSP/A3N kidney tubule regeneration foci count control condition Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 1.3 /section 0.3 ex vivo light microscopy with histochemistry 0.0 0 107546 3090
SHRSP/A3N kidney tubule regeneration foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 27.3 /section 2.9 ex vivo light microscopy with histochemistry 0.0 0 107547 3090
SHRSP/A3N systolic blood pressure controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. arterial blood pressure trait male 203 days-224 days 10 267.0 mmHg 7.0 22.14 tail cuff plethysmography tail 0.0 0 high salt high fat diet 107096 3075
SHRSP/A3N body weight standard condition (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. body mass male 203 days-224 days 10 341.0 g 4.0 12.65 body weighing method 0.0 0 standard rat chow 107106 3075
SHRSP/A3N heart rate controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 203 days-224 days 10 280.0 beats/min 4.0 12.65 tail cuff plethysmography 0.0 0 high salt high fat diet +carvedilol 107116 3075
SHRSP/A3N heart rate controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 203 days-224 days 10 341.0 beats/min 20.0 63.25 tail cuff plethysmography 0.0 0 high salt high fat diet 107117 3075
SHRSP/A3N heart rate standard condition (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 203 days-224 days 10 364.0 beats/min 24.0 75.89 tail cuff plethysmography 0.0 0 standard rat chow 107118 3075
SHRSP/A3N body weight controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. body mass male 203 days-224 days 10 329.0 g 6.0 18.97 body weighing method 0.0 0 high salt high fat diet 107104 3075
SHRSP/A3N end-diastolic volume controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 189 days-210 days 0 0.69 ml 0.05 transthoracic echocardiography 0.0 0 high salt high fat diet 107122 3075
SHRSP/A3N end-diastolic volume standard condition Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 189 days-210 days 0 0.78 ml 0.01 transthoracic echocardiography 0.0 0 standard rat chow 107123 3075
SHRSP/A3N renal fibrosis foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 25.0 /section 1.0 ex vivo light microscopy with histochemistry 0.0 0 foci of renal fibrosis 107497 3088
SHRSP/A3N serum free fatty acids level control condition Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. blood free fatty acid amount female 120 days-140 days 24 180.0 mmol/l 16.0 78.38 automated serum analysis 0.0 0 107618 3093